trial

Quetiapine and the Dopaminergic Epigenetic Control

NCTId NCT00370500
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 100 (actual)
Sponsored by University of Erlangen-Nürnberg Medical School
Primary completion 2008-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
100 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2007-04
Primary completion
2008-07
Eligibility
MALE · 18 Years · 65 Years

Interventions & indications

Drugs
Quetiapine

Sponsors

University of Erlangen-Nürnberg Medical SchoolLead Sponsor
AstraZenecaCollaborator

Investigators

1
Stefan Bleich, MDPrincipal Investigator

Sites

1 total
Erlangen, Germany

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE4
Primary Completion Date
2008-07
Status
COMPLETED
relationships
The graph out of here
drug
Quetiapine
drug
lead_sponsor
University of Erlangen-Nürnberg Medical School
company
collaborator
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Stefan Bleich, MD
person